Novo Nordisk launches Awiqli, described as the world’s first once-weekly basal insulin, in India. The insulin is intended for adults with type 1 and type 2 diabetes and aims to reduce the treatment burden by cutting the number of injections from about 365 per year to 52 per year. Multiple reports say the product is positioned to help address delays in insulin initiation, alongside the convenience of weekly dosing.
Business Line reports that Awiqli is imported from Denmark. It is listed at ₹2,611 for a 1 ml pen, which contains 700 insulin units. Other coverage focuses on the expected clinical and practical impact of switching from daily basal insulin injections to a weekly schedule for eligible patients.
While the sources emphasize the product’s availability and dosing rationale, they do not provide detailed efficacy or safety comparison data in the supplied excerpts. Overall, the reporting centers on the India launch, intended patient population, weekly injection schedule, import origin, and the stated pricing.
